Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (C.R.P. Test, C.C.P., E.S.R. Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores) – Industry Trends and Forecast to 2030.
Arthritis Market Analysis and Size:
The increasing prevalence of arthritis and advances in technology have significantly improved the design and functionality of arthritis treatment and have carved the way for the growth of the arthritis market. The arthritis market has been growing steadily due to several factors. Firstly, developing new and improved treatment options for arthritis has been a driver in the market. Additionally, there is an increasing focus on personalized medicine in treating arthritis.
Data Bridge Market Research analyses that the global arthritis market, which was USD 4.3 billion in 2022, would rocket up to USD 8.63 billion by 2030 and is expected to undergo a CAGR of 9.10% during the forecast period. This indicates that the biologics segment dominates the rheumatoid drug type segment of the arthritis market. The advancements in technology have led to the development of rapid and implant drugs and treatments for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Arthritis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021(Customizable year 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (C.R.P. Test, C.C.P., E.S.R. Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Johnson & Johnson Private Limited(U.S.), AbbVie Inc. (U.S.); Pfizer Inc. (U.S.); Amgen Inc. (U.S.); Bristol-Myers Squibb Company(U.S.); F. Hoffmann-La Roche Ltd.(U.S.); U.C.B. S.A.(Belgium), Gilead Sciences, Inc. (U.S.); Boehringer Ingelheim International GmbH.(Germany) Lilly(U.S.), Sanofi (France), Novartis AG (Switzerland), AstraZeneca; Astellas Pharma Inc.(Japan), Galapagos NV(Belgium), Taisho Pharmaceutical Holdings Co., Ltd.(U.K.), Regeneron Pharmaceuticals Inc.(U.S.) Swedish Orphan Biovitrum AB (publ) (Sweden), ABIOGEN PHARMA S.p.A (Italy), Kolon TissueGene, Inc.(U.S.), Ampio Pharmaceuticals Inc. .(U.S.), Merck Sharp & Dohme Corp. .(U.S.), and GlaxoSmithKline plc (U.K.)
|
|
Market Opportunities
|
|
Market Definition
The global arthritis market refers to the commercial and therapeutic landscape related to the diagnosis, treatment, and management of arthritis, a group of musculoskeletal conditions characterized by inflammation and stiffness of joints. Arthritis is a prevalent chronic disease that can affect people of all ages, causing pain, impaired mobility, and decreased quality of life.
The global arthritis market encompasses various products and services aimed at addressing the needs of patients with arthritis, including pharmaceuticals, biologics, medical devices, diagnostic tools, and supportive therapies. It also includes research and development activities, clinical trials, and the regulatory framework associated with arthritis treatments.
Global Arthritis Market Dynamics
Drivers
- Increasing Prevalence of Arthritis
The rising prevalence of arthritis, including rheumatoid arthritis, osteoarthritis, and psoriatic arthritis, is a significant market driver. Factors such as aging populations, sedentary lifestyles, obesity, and genetic predisposition contribute to the growing number of arthritis cases worldwide.
- Growing Awareness and Diagnostics
There is an increasing awareness of arthritis and its impact on individuals' quality of life. This has led to improved diagnosis rates and early detection of the disease. Greater awareness among both patients and healthcare professionals helps in timely intervention and treatment, driving the demand for arthritis management solutions.
- Advancements Treatment Options
The arthritis market has witnessed significant advancements in treatment options, including pharmacological interventions, biological therapies, and non-pharmacological approaches such as physical therapy and exercise. These innovations have improved the management of arthritis, providing patients with more effective and personalized treatment options.
Opportunities
- Rising Biologic Therapies
Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (J.A.K.) inhibitors, have revolutionized the treatment of arthritis. However, there is still room for improvement in efficacy, safety, and personalized treatment options. Developing innovative biologics with improved efficacy and reduced side effects can be a significant opportunity in the market.
- Rising Patient Education and Support:
Arthritis is a chronic condition that requires self-management and lifestyle modifications. Providing education, support, and resources to patients and their caregivers can improve treatment adherence and outcomes. Digital health platforms, mobile applications, and telemedicine services can significantly deliver patient education and support.
Restraints/Challenges
- High Treatment Costs
Arthritis management often requires long-term medication and therapy, which can be expensive. The high cost of treatment, including prescription medications, physical therapy, and surgeries, can be a significant barrier for patients, particularly in countries with limited access to healthcare or inadequate insurance coverage. Affordability issues can hinder patients' ability to receive necessary treatment and limit market growth.
- Limited Efficacy of Available Treatments
While various treatment options are available for arthritis, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic therapies, not all patients respond adequately to these treatments. Some patients may experience only partial relief of symptoms or no improvement at all. The limited efficacy of existing treatments can restrict market growth and drive the need for innovative therapies.
This global arthritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global arthritis market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed decision to achieve market growth.
Recent Development
- In December 2022, Merck KGaA, a leading science and technology company, announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, U.S.A, to discover novel antibody-drug conjugates (A.D.C.s) leveraging Mersana's proprietary Immunosynthen STING-agonist A.D.C. platform, directed against up to two targets
- In February 2023, Roche announced that it had expanded its collaboration with Janssen Biotech Inc. (Janssen) to create companion diagnostics for targeted therapies, further strengthening research and innovation activities
Global Arthritis Market Scope
The global arthritis market is segmented on the basis of Rheumatoid Drug Type, Rheumatoid Treatment, Rheumatoid Diagnosis, Osteoarthritis Type, Osteoarthritis Treatment, Osteoarthritis Diagnosis, Route of Administration, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Rheumatoid Drug Type
- Biologics
- Non-Biologics
- Steroids
- Analgesics
- Glucocorticoids
- Others
Rheumatoid Treatment
- Synovectomy
- Tendon Repair
- Joint Fusion
- Symptomatic Treatment
- Intermediate Corticosteroid Therapies
- DMARD Therapies
Rheumatoid Diagnosis
- C.R.P. Test
- CCP
- ESR Test
Osteoarthritis Type
- Hip
- Spinal
- Knee
- Foot and Ankle
- Shoulder
- Hand
Osteoarthritis Treatment
- Medication
- Drugs
- Assistive Devices
- Surgery
- Therapy
Osteoarthritis Diagnosis
- Imaging
- Joint Fluid Analysis
- Others
Route of Administration
- Oral
- Parenteral
End user
- Hospitals,
- Clinics
- Household
- Medical Institutes
- Research Organizations,
- Others
Global Arthritis Market Regional Analysis/Insights
The global arthritis market is analyzed, and market size insights and trends are provided for product type, biomaterial, procedure, device type, application, and end-user, as referenced above.
The countries covered in the global arthritis market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, the Rest of South America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of the Middle East and Africa.
North America dominates the arthritis market due to the presence of major key players, high disposable income, high healthcare expenditure, and a well-developed healthcare sector in this region.
Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends and Porter’s five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global arthritis market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Global arthritis market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the Global arthritis market. The data is available for the historical period 2015-2020.
Competitive Landscape and Global Arthritis Market Share Analysis
The global arthritis market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the global arthritis market.
Some of the major players operating in the global arthritis market are:
- Johnson & Johnson Private Limited(U.S.)
- AbbVie Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Amgen Inc. (U.S.)
- Bristol-Myers Squibb Company(U.S.)
- F. Hoffmann-La Roche Ltd.(U.S.)
- UCB S.A.(Belgium)
- Gilead Sciences, Inc. (U.S.)
- Boehringer Ingelheim International GmbH.(Germany)
- Lilly(U.S.)
- Sanofi (France)
- Novartis AG (Switzerland)
- AstraZeneca(U.S.)
- Astellas Pharma Inc.(Japan)
- Galapagos NV (Belgium)
- Taisho Pharmaceutical Holdings Co., Ltd.(U.K.)
- Regeneron Pharmaceuticals Inc.(U.S.)
- Swedish Orphan Biovitrum AB (publ) (Sweden)
- ABIOGEN PHARMA S.p.A (Italy)
- Kolon TissueGene, Inc.(U.S.)
- Ampio Pharmaceuticals Inc. .(U.S.)
- Merck Sharp & Dohme Corp. .(U.S.),
- GlaxoSmithKline plc (U.K.)
SKU-